Paulovich Laboratory at Fred Hutch Earns CAP Accreditation

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is proud to announce that the Paulovich Laboratory at Fred Hutchinson Cancer Center (Fred Hutch) has achieved accreditation from the College of American Pathologists (CAP). This significant milestone positions the lab and the consortium as a whole to more effectively translate proteomic discoveries into clinical practice by demonstrating adherence to a globally recognized standard of quality and patient safety.

"We want to adhere to the highest standards when testing clinical specimens," said Jeffrey Whiteaker, PhD, Director of Proteomics at the Paulovich Lab. "CAP accreditation is widely recognized as a gold standard, with a rigorous on-site inspection process that ensures quality and consistency. Its standards often exceed federal requirements, which is crucial for our scientific goals."

The Paulovich Laboratory was founded to address a lack of adequate diagnostics for early detection and cancer treatment response prediction in precision oncology. For more than 22 years, the lab has developed, validated and standardized tools for quantifying human proteins, shared standardized tools and assays, and fostered international public-private partnerships to achieve this goal. On its website, the lab envisions “a day when any human protein of interest can be reliably quantified (and thus effectively studied) by any researcher in the world.” 

"It’s tremendously satisfying to achieve the accreditation, and going through the process has given our staff training that will continually improve our lab going forward," Dr. Whiteaker added. "Ultimately, this is a process where we continually improve our measurements. My hope is that we will be able to contribute to clinical diagnostics by providing the best proteomics measurements possible."